Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Herman Yeger

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Cancers|July 24, 2021
The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance ImmunotherapyReza Bayat Mokhtari, Manpreet Sambi, Bessi Qorri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2011
Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumorSushil Kumar, Reza Bayat Mokhtari, Reihaneh Sheikh, et al.
Neoplasia (New York, N.Y.)|May 5, 2009
In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse modelLibo Zhang, Kristen M Smith, Amy L Chong, et al.
Proteomics|October 22, 2014
The major cystic fibrosis causing mutation exhibits defective propensity for phosphorylationStan Pasyk, Steven Molinski, Saumel Ahmadi, et al.
Translational Oncology|May 27, 2018
Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft ModelsSushil Kumar, Jessica D Sun, Libo Zhang, et al.
Cell Death & Disease|August 9, 2022
Genetic alterations of Keap1 confers chemotherapeutic resistance through functional activation of Nrf2 and Notch pathway in head and neck squamous cell carcinomaSyed S Islam, Khawlah Qassem, Shafiqul Islam, et al.
The American Journal of Pathology|March 14, 2002
The expression of ccn3(nov) gene in musculoskeletal tumorsMaria Cristina Manara, Bernard Perbal, Stefania Benini, et al.
Molecular Therapy. Methods & Clinical Development|January 6, 2016
Testing gene therapy vectors in human primary nasal epithelial culturesHuibi Cao, Hong Ouyang, Wan Ip, et al.
Oncotarget|July 28, 2021
Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosisReza Bayat Mokhtari, Bessi Qorri, Narges Baluch, et al.
Oncotarget|September 12, 2022
Correction: Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosisReza Bayat Mokhtari, Bessi Qorri, Narges Baluch, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Cancers|July 24, 2021
The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance ImmunotherapyReza Bayat Mokhtari, Manpreet Sambi, Bessi Qorri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2011
Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumorSushil Kumar, Reza Bayat Mokhtari, Reihaneh Sheikh, et al.
Neoplasia (New York, N.Y.)|May 5, 2009
In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse modelLibo Zhang, Kristen M Smith, Amy L Chong, et al.
Proteomics|October 22, 2014
The major cystic fibrosis causing mutation exhibits defective propensity for phosphorylationStan Pasyk, Steven Molinski, Saumel Ahmadi, et al.
Translational Oncology|May 27, 2018
Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft ModelsSushil Kumar, Jessica D Sun, Libo Zhang, et al.
Cell Death & Disease|August 9, 2022
Genetic alterations of Keap1 confers chemotherapeutic resistance through functional activation of Nrf2 and Notch pathway in head and neck squamous cell carcinomaSyed S Islam, Khawlah Qassem, Shafiqul Islam, et al.
The American Journal of Pathology|March 14, 2002
The expression of ccn3(nov) gene in musculoskeletal tumorsMaria Cristina Manara, Bernard Perbal, Stefania Benini, et al.
Molecular Therapy. Methods & Clinical Development|January 6, 2016
Testing gene therapy vectors in human primary nasal epithelial culturesHuibi Cao, Hong Ouyang, Wan Ip, et al.
Oncotarget|July 28, 2021
Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosisReza Bayat Mokhtari, Bessi Qorri, Narges Baluch, et al.
Oncotarget|September 12, 2022
Correction: Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosisReza Bayat Mokhtari, Bessi Qorri, Narges Baluch, et al.
Pageof 10